Selective T-cell (lymphocyte) costimulation blocker

A selective T-cell (lymphocyte) costimulation blocker is an immunosuppressive drug class, categorized by the FDA as an Established Pharmacologic Class, that prevents full T-lymphocyte activation by interfering with essential secondary costimulatory signals Clinically, members of this therapeutic category, most notably belatacept, are primarily indicated for the prophylaxis of organ rejection in adult kidney transplant recipients as an alternative to calcineurin inhibitors, while closely related ...

A selective T-cell (lymphocyte) costimulation blocker is an immunosuppressive drug class, categorized by the FDA as an Established Pharmacologic Class, that prevents full T-lymphocyte activation by interfering with essential secondary costimulatory signals

Structurally engineered as recombinant fusion proteins linking the extracellular domain of cytotoxic T-lymphocyte antigen 4 (CTLA-4) to an immunoglobulin Fc region, these agents bind specifically to CD80 and CD86 ligands on antigen-presenting cells to competitively inhibit their binding with CD28 on T cells Clinically, members of this therapeutic category, most notably belatacept, are primarily indicated for the prophylaxis of organ rejection in adult kidney transplant recipients as an alternati...

Structurally engineered as recombinant fusion proteins linking the extracellular domain of cytotoxic T-lymphocyte antigen 4 (CTLA-4) to an immunoglobulin Fc region, these agents bind specifically to CD80 and CD86 ligands on antigen-presenting cells to competitively inhibit their binding with CD28 on T cells

Clinically, members of this therapeutic category, most notably belatacept, are primarily indicated for the prophylaxis of organ rejection in adult kidney transplant recipients as an alternative to calcineurin inhibitors, while closely related costimulation modulators treat autoimmune disorders such as rheumatoid arthritis